يعرض 1 - 10 نتائج من 61 نتيجة بحث عن '"Im S.-A."', وقت الاستعلام: 1.60s تنقيح النتائج
  1. 1
    Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    المؤلفون: Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmana, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S. A., Jager, A., Lakhani, S. R., Janni, W., Linderholm, Barbro, 1959, Liu, T. W., Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marme, F., de Duenas, E. M., McConnell, R., Phillips, K. A., Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Spanic, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I., Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J., Johannsson, O. T.

    المصدر: Annals of Oncology. 33(12):1250-1268

    مصطلحات موضوعية: Cancer and Oncology, Cancer och onkologi, breast cancer, BRCA1/2, PARP inhibition, olaparib, adjuvant therapy

    الوصول الحر: https://gup.ub.gu.se/publication/324088Test


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis.

    المؤلفون: Park, Y.H.1 (AUTHOR), Im, S-A.2 (AUTHOR), Ahn, J-H.3 (AUTHOR), Kim, M.H.4 (AUTHOR), Cortés, J.5 (AUTHOR), Dent, R.A.6 (AUTHOR), Pusztai, L.7 (AUTHOR), McArthur, H.L.8 (AUTHOR), Kummel, S.9 (AUTHOR), Denkert, C.10 (AUTHOR), O'Shaughnessy, J.11 (AUTHOR), Mouret-Reynier, M-A.12 (AUTHOR), Ferreira, M.I.R.13 (AUTHOR), Gion Cortes, M.14 (AUTHOR), Boileau, J-F.15 (AUTHOR), Hui, R.16 (AUTHOR), Zhu, Y.17 (AUTHOR), Pan, W.17 (AUTHOR), Karantza, V.V.17 (AUTHOR), Schmid, P.18 (AUTHOR)

    المصدر: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1467-S1468. 2p.

    مصطلحات موضوعية: *TRIPLE-negative breast cancer, *SUBGROUP analysis (Experimental design), *PEMBROLIZUMAB, *PLACEBOS


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial.

    المؤلفون: Yap, Y-S.1 (AUTHOR), Im, S-A.2 (AUTHOR), Lu, Y-S.3 (AUTHOR), Azim, H.A.4 (AUTHOR), Eralp, Y.5 (AUTHOR), Kanakasetty, G.B.6 (AUTHOR), Abdel-Razeq, H.7 (AUTHOR), Zhukova, L.8 (AUTHOR), Thuerigen, A.9 (AUTHOR), Delgar Alfaro, T.10 (AUTHOR), Wu, J.11 (AUTHOR), Gao, M.12 (AUTHOR), El Saghir, N.S.13 (AUTHOR)

    المصدر: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1488-S1488. 1p.

    مصطلحات موضوعية: *METASTATIC breast cancer, *HORMONE therapy, *COMBINATION drug therapy


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)

    المؤلفون: Cortés, J.1 (AUTHOR), Im, S-A.2 (AUTHOR), Iwata, H.3 (AUTHOR), Hamilton, E.P.4 (AUTHOR), Hurvitz, S.A.5 (AUTHOR), Egorov, A.6 (AUTHOR), Cathcart, J.7 (AUTHOR), Liu, Y.8 (AUTHOR), Bako, E.9 (AUTHOR), Curigliano, G.10 (AUTHOR)

    المصدر: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS645-S646. 2p.

    مصطلحات موضوعية: *METASTATIC breast cancer, *TRASTUZUMAB, *SUBGROUP analysis (Experimental design)

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    284P Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study.

    المؤلفون: Im, S-A.1 (AUTHOR), Park, I.2 (AUTHOR), Sohn, J.H.3 (AUTHOR), Im, Y-H.4 (AUTHOR), Lee, S.C.5 (AUTHOR), Chang, H-K.5 (AUTHOR), Macharia, H.6 (AUTHOR), Sun, G.7 (AUTHOR), Lamour, F.8 (AUTHOR), Oh, D-Y.9 (AUTHOR)

    المصدر: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS488-S489. 2p.

    مصطلحات موضوعية: *METASTATIC breast cancer, *ASIANS, *TRASTUZUMAB

    النص الكامل

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

    المؤلفون: Im, S-A.1, Tan, A.R.2, Mattar, A.3, Colomer, R.4, Stroyakovskii, D.5, Nowecki, Z.6, De Laurentiis, M.7, Pierga, J-Y.8, Jung, K.H.9, Schem, C.10, Aguila, C.11, Badovinac Crnjevic, T.11, Heeson, S.12, Shivhare, M.13, Alexandrou, A.14, Restuccia, E.11, Jackisch, C.15

    المصدر: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS40-S41. 2p.

    مصطلحات موضوعية: *BREAST cancer treatment, *TRASTUZUMAB, *COMBINATION drug therapy

    النص الكامل

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    127P Lactobacillus plantarum IMB19 exerts anti-tumor immunity by enhancing effector functions of tumor associated type 1 macrophage and CD8+ T-cells.

    المؤلفون: Im, S-H.1 (AUTHOR)

    المصدر: Annals of Oncology. 2021 Supplement 7, Vol. 32, pS1433-S1433. 1p.

    مصطلحات موضوعية: *IMMUNE response, *LACTOBACILLUS plantarum, *CD8 antigen, *T cells, *IMMUNITY

    النص الكامل

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    270P Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer.

    المؤلفون: Im, S-A.1 (AUTHOR), Kim, J.E.2 (AUTHOR), Lee, K.S.3 (AUTHOR), Moon, Y.W.4 (AUTHOR), Ahn, H.K.5 (AUTHOR), Ock, C-Y.6 (AUTHOR), Roh, E-J.6 (AUTHOR), Lee, M.6 (AUTHOR), Hong, M.J.6 (AUTHOR), Song, S.6 (AUTHOR), Lee, K-H.1 (AUTHOR), Lee, W.S.6 (AUTHOR)

    المصدر: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS480-S480. 1p.

    مصطلحات موضوعية: *BREAST cancer, *POLY(ADP-ribose) polymerase

    النص الكامل

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC).

    المؤلفون: Sonnenblick, A.1 (AUTHOR), Im, S-A.2 (AUTHOR), Lee, K.S.3 (AUTHOR), Tan, A.4 (AUTHOR), Telli, M.5 (AUTHOR), Strulov Shachar, S.6 (AUTHOR), Bene Tchaleu, F.7 (AUTHOR), Cha, E.8 (AUTHOR), DuPree, K.9 (AUTHOR), Nikanjam, M.10 (AUTHOR), Shemesh, C.11 (AUTHOR), Xu, J.12 (AUTHOR), Zhang, X.13 (AUTHOR), Zhu, J.14 (AUTHOR), Rugo, H.S.15 (AUTHOR)

    المصدر: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS479-S479. 1p.

    مصطلحات موضوعية: *BREAST cancer, *ATEZOLIZUMAB

    النص الكامل

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    234P Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)

    المؤلفون: Rugo, H.S.1 (AUTHOR), Im, S-A.2 (AUTHOR), Joy, A.A.3 (AUTHOR), Yaroslav, S.4 (AUTHOR), Walshe, J.M.5 (AUTHOR), Sleckman, B.6 (AUTHOR), Loi, S.7 (AUTHOR), Puyana Theall, K.8 (AUTHOR), Kim, S.9 (AUTHOR), Huang, X.9 (AUTHOR), Bananis, E.10 (AUTHOR), Mahtani, R.11 (AUTHOR), Finn, R.S.12 (AUTHOR), Diéras, V.13 (AUTHOR)

    المصدر: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS461-S461. 1p.

    مصطلحات موضوعية: *EPIDERMAL growth factor receptors, *BREAST cancer, *HORMONE therapy, *CANCER chemotherapy

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث